PepGen Inc. announced key highlights from the upcoming presentation of preclinical non-human primate (NHP) data supporting PepGen's proprietary Enhanced Delivery Oligonucleotide (EDO) platform at the 6th Ottawa International Conference on Neuromuscular Disease and Biology (NMD) being held on September 7-9, 2023 in Ottawa, ON, Canada, and at the 2023 Myotonic Dystrophy Foundation (MDF) Annual Conference being held on September 7- 9, 2023 in Ottawa,ON, Canada, and at the2023 Myotonic Dy Strophy Foundation (MDF) annual Conference being held on September 7, 2023 in Washington, D.C. In a poster presentation titled PGN-EDODM1 Nonclinical Data Demonstrate Mechanistic and Meaningful Activity for potential Treatment of Myotonic Dystrophy Type 1 at MDF and FREEDOM-DM1: Nonclinical Data Support the Phase 1 Study Design to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM 1 in Adults with Myotonic Dystrophy type 1 (DM1) at NMD, PepGen reported that the EDO technology enables up to 25-fold higher level of nuclear delivery of oligonucleotides in vitro to myotubes compared to naked unconjugated oligonucleotides. Additionally, the presentation reported that EDO technology was also shown to improve in vivo nuclear delivery, with 72% of skeletal muscle nuclei in NHPs positive for oligonucleotide following two doses at 30mg/kg. The congenital form of DM1 is the most severe version and can be life-threatening.